Intended for healthcare professionals


Stepping into the therapeutics void

BMJ 2009; 338 doi: (Published 05 January 2009) Cite this as: BMJ 2009;338:a3179
  1. Rebecca Coombes
  1. 1London

    As the number of therapeutics departments in medical schools falls, Rebecca Coombes hears how the drug industry is stepping into the breach

    Drug company staff are providing direct teaching to UK undergraduate medical students, a model that the industry hopes can be developed to forge valuable links with trainee doctors.

    The move comes as many medical schools are moving investment away from clinical pharmacology to concentrate on research.

    Pfizer has a contract to deliver a module to undergraduates at Brighton and Sussex Medical School, a new school that does not have a clinical pharmacology department. Pfizer does not charge for its services, and students travel to the company’s headquarters in Walton Oaks, Surrey, for a series of seminars with staff.

    The Association of the British Pharmaceutical Industry (ABPI) is also delivering talks to undergraduates at several medical schools. Richard Tiner, its medical director, said he was in talks with senior lecturers, including at the University of Leeds School of Medicine, to provide general talks on the industry, drug development, and adverse drug reactions. He believes that UK medical academics were becoming more receptive to offers of help from the industry.

    “Three to four years ago we weren’t doing anything like this. Last month we had two such talks in a week,” he …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription